GHSG-AFM13 An Open-label, Randomized, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Jul 2019
Price : $35 *
At a glance
- Drugs AFM 13 (Primary)
- Indications Hodgkin's disease
- Focus Proof of concept; Therapeutic Use
- Acronyms GHSG-AFM13
- 19 Jul 2019 Planned primary completion date changed from 1 Aug 2018 to 1 Dec 2020.
- 19 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Dec 2017 Planned number of patients changed from 39 to 49.